Company profile
LB PHARMACEUTICALS INC
NASDAQ:LBRXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| LB-102 | phase3 | — | 6 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07369154 | phase3 | recruiting | 2026-04-23 | 2028-12-01 | LB Pharmaceuticals Inc. | 52-week Open Label Safety-Tolerability Study |
| NCT07494305 | phase2 | recruiting | 2026-01-23 | 2028-02-01 | LB Pharmaceuticals Inc. | Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. |
| NCT06179108 | phase2 | completed | 2023-11-29 | 2024-12-04 | LB Pharmaceuticals Inc. | Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia |
| NCT04588129 | phase1 | completed | 2021-01-05 | 2021-09-17 | LB Pharmaceuticals Inc. | Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers |
| NCT04187560 | phase1 | completed | 2020-01-22 | 2020-07-01 | LB Pharmaceuticals Inc. | Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults |
FDA applications (0)
No records yet.